We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

BRCA-Negative Results May Not Reduce Cancer Risk

By LabMedica International staff writers
Posted on 12 Dec 2013
Genetic changes in breast cancer genes are known to carry a higher risk, but even family members who test negative for the genetic differences are still at an increased probability of developing the disease. More...


The credence that a woman from a family with breast cancer gene (BRCA) mutations who tests negative for her family-specific BRCA mutation has the same chances of contracting the disease as someone in the general population has been challenged.

Scientists at the University of Manchester (UK) identified 807 BRCA families, including information about whether or not relatives had been tested. DNA was extracted from blood samples provided by women attending the genetic clinics. In addition to the BRCA1/2 mutation analysis, women were genotyped for 18 single nucleotide polymorphisms (SNPs) that have been shown to be associated with breast cancer risk in the general population and a subset of SNPs in familial breast cancer.

The investigators found that found that 49 women who had tested negative for the BRCA mutation had subsequently developed breast cancer. Even when the scientists factored in age, they found that in each age group, there were about twice as many cases of breast cancer as would be expected within the general population. Of the 49 women, 22 were among 279 women who tested negative from BRCA1 families, and 27 were among the 251 women who tested negative to BRCA2 mutations.

They also found that the women from BRCA1 families did not experience any increased risk, but the observed versus expected ratio (O/E) for women from BRCA2 families was 4.57 which led to the conclusion that BRCA-negative women from BRCA2 families face a fourfold increased risk of developing breast cancer.

Gareth R Evans, MD, FRCP, a professor and the lead author of the study said, “About 77 single nucleotide polymorphisms (SNPs), the genetic variations that can help track the inheritance of disease genes within families, are linked to breast cancer risk. Identification of additional SNPs is necessary to understand why some of the BRCA-negative women from BRCA families are at higher risk. If there is a strong family history of breast cancer in a BRCA2 family, for example with a mother and sister diagnosed under the age of 50, they should seek additional screening even if had tested negative previously.” The study was published on November 27, 2013, in the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:

University of Manchester 



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.